NEW YORK, June 30, 2016 /PRNewswire/ --

Lagging the market yesterday was the Biotech space, which continues to be challenged by costs, economic uncertainty, and policies. Stock-Callers.com reviews the recent performances of the following equities today: ImmunoGen Inc. (NASDAQ: IMGN), Immunomedics Inc. (NASDAQ: IMMU), Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR). Sign up for your complimentary trade alerts on these stocks at:

http://stock-callers.com/registration  

To access Stock-Callers.com full PDF Research Packages for free, please visit the links below.

============

Full PDF DOWNLOAD Links 

(You may have to copy and paste the links into your browser)

IMGN Research Package: http://stock-callers.com/registration/?symbol=IMGN

IMMU Research Package: http://stock-callers.com/registration/?symbol=IMMU

VNDA Research Package: http://stock-callers.com/registration/?symbol=VNDA

ARWR Research Package: http://stock-callers.com/registration/?symbol=ARWR

============

Waltham, Massachusetts headquartered biotechnology Company ImmunoGen Inc.'s stock finished Wednesday's session at $3.13, which was a decline of 1.57%. A total volume of 2.03 million shares was traded. The Company's shares are trading 45.02% below their 50-day moving average. Additionally, shares of ImmunoGen, which develops targeted anticancer therapeutics, have a Relative Strength Index (RSI) of 22.92.

On Wednesday, shares in Morris Plains, New Jersey headquartered clinical-stage biopharmaceutical Company, Immunomedics Inc., recorded a trading volume of 2.35 million shares, which was above their three months average volume of 2.26 million shares. The stock ended the session 3.21% higher at $2.25. The Company's shares are trading 18.26% below their 200-day moving average. Moreover, shares of Immunomedics, which focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other diseases, have an RSI of 32.47.

Shares in Washington, the District of Columbia headquartered biopharmaceutical Company, Vanda Pharmaceuticals Inc., closed the day 0.63% lower at $11.11. The stock recorded a trading volume of 430,227 shares. The Company's shares have gained 6.83% in the last month, 32.89% in the previous three months, and 19.33% on an YTD basis. The stock is trading 12.44% above its 50-day moving average and 16.60% above its 200-day moving average. Additionally, shares of Vanda Pharmaceuticals, which focuses on the development and commercialization of products for the treatment of central nervous system disorders, have an RSI of 57.77.

At the close, shares in Pasadena, California headquartered biopharmaceutical Company, Arrowhead Pharmaceuticals Inc., ended the day at $5.41, gaining 1.88%. The stock recorded a trading volume of 351,782 shares. The Company's shares have advanced 12.24% in the previous three months. The stock is trading above its 200-day moving average by 1.70%. Furthermore, shares of Arrowhead Pharmaceuticals, which develops novel drugs to treat intractable diseases in the U. S., have an RSI of 41.64.

--

Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFA(R) charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

http://stock-callers.com/legal-disclaimer

        
         
        CONTACT 
        For any questions, inquiries, or comments reach out to us directly. If you're a company
         we are covering and wish to no longer feature on our coverage list contact us via
         email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:  
        EmptyBreak:MARKER 
        Email: info@stock-callers.com 
        Phone number:  +44 330 808 3765 
        Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2
         1BP 

 

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA